Viking Therapeutics’ stock has climbed after another company’s disappointing results in the first late-stage clinical trial of a fatty liver disease.
BIOTECH: M&A in the Air at Contract Research Organizations
A crop of San Diego companies quietly play niche roles in drug development. But suitors have taken notice.
Dexcom in fourth quarter financials reported that revenue shot up 53 percent year-over-year to $338 million.
A wide-ranging patent dispute between San Diego-based ResMed and Fisher & Paykel Healthcare has come to an end.
NuVasive reported net income of $12.2 million, or $0.23 per share, in fourth quarter results.
Scripps Mercy Hospital San Diego landed a $260,000 grant for opioid disorder treatment, the California Bridge Program recently announced.
San Diego-based Amplyx Pharmaceuticals’ lead drug candidate received an orphan drug designation for a condition that can be life-threatening for HIV/AIDs patients and others.
AMN Healthcare recently reported $529 million in fourth quarter revenue, a 4 percent year-over-year increase. San Diego-based AMN is the country’s largest health care staffing agency.
A recent report stated that Smith & Nephew Plc has held talks to buy San Diego spine surgery company NuVasive. But analysts largely said the deal doesn’t make sense for the British firm.
The 350 attendees are proven men and women of action.